Article
miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.
Neoplasia (New York, N.Y.) - 1 Dec 2020
Nguyen Mai-Huong Thi, Lin Chen-Huan, Liu Szu-Mam, Miyashita Azusa, Ihn Hironobu, Lin Hsuan, Ng Chi Hou, Tsai Jen-Chieh, Chen Ming-Hong, Tsai Mu-Shiun, Lin In-Yu, Liu Shu-Chen, Li Long-Yuan, Fukushima Satoshi, Lu Jean, Ma Nianhan
Abstract excerpt
BRAF inhibitors were approved for the treatment of BRAF-mutant melanoma. However, most patients acquire the resistance to BRAF inhibitors after several months of treatment. miR-524-5p is considered as a tumor suppressor in many cancers, including melanoma. In this study, we investigated the biological functions of miR-524-5p in melanoma with acquired resistance to BRAF inhibitor and evaluated the endogenous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.